Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced a fifth amendment to its accounts receivable agreement with Oasis Capital, LLC, allowing the purchase of additional accounts receivable totaling $3,810,587.04 from October 13 to December 2, 2020. This financing represents a strategic move to secure non-dilutive capital as the company sees growing sales of its Mytesi drug product.
Oasis will pay $1,619,499.49 for these receivables and charge a 5.45% fee. This indicates an increase in the financing percentage compared to previous agreements.
Jaguar Health (NASDAQ:JAGX) and Napo Pharmaceuticals plan to develop crofelemer for treating inflammatory diarrhea in long-hauler COVID-19 patients in Europe. Preliminary discussions with Swiss Growth Forum involve a SPAC merger, offering Napo a cash license fee between $2M-$10M and at least $20M for European operations. Crofelemer, an FDA-approved medication for noninfectious diarrhea in HIV/AIDS patients, aims to address chronic gastrointestinal issues post-COVID. Jaguar emphasizes the significance of early diagnosis to improve long-term recovery outcomes.
Jaguar Health, Inc. (NASDAQ:JAGX) has released a podcast interview with CEO Lisa Conte via The Wall Street Resource. The company focuses on developing plant-based, non-opioid medications for gastrointestinal issues, particularly targeting chronic diarrhea. Their flagship product, Mytesi (crofelemer), is FDA-approved for treating non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company emphasizes sustainable sourcing of ingredients, highlighting ecological integrity in harvesting practices.
Jaguar Health reported third quarter 2020 financial results, showing significant growth in Mytesi product revenue totaling approximately $2.8 million, a 280% increase from $1.0 million in the same quarter of 2019. Gross sales reached approximately $6.3 million, up 332% year-over-year. Despite increased sales, the company recorded a net loss of $7.9 million, compared to $7.6 million in Q3 2019. Operating expenses rose to $8.1 million, influenced by higher general and administrative costs, including a $2.5 million trial delay fee.
Jaguar Health, Inc. (NASDAQ:JAGX) is set to file its Q3 2020 10-Q report on November 16, 2020. Management will host a conference call at 8:30 a.m. ET to discuss the financial results and provide business updates. Investors can join via dial-in numbers, with a replay option also available. The company is focused on developing plant-based pharmaceuticals to address GI distress, particularly chronic diarrhea. Notably, its product Mytesi® is FDA-approved for treating diarrhea in adults with HIV/AIDS.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that it received an extension from the Nasdaq Hearings Panel until December 23, 2020, to comply with the minimum bid price requirement for continued listing. The company must maintain a bid price of at least $1.00 per share for ten consecutive business days. Jaguar's recent efforts include expanded access programs for Mytesi and a $6 million royalty-based capital infusion. Additionally, Napo Pharmaceuticals initiated a pivotal Phase 3 trial for Mytesi in adult cancer patients experiencing diarrhea.
Jaguar Health (NASDAQ:JAGX) is hosting its inaugural "Diarrhea Dialogues" virtual event on October 20, 2020, from 3:00 PM to 4:30 PM ET, focused on supportive care for cancer patients experiencing diarrhea from cancer therapies. Key experts, including Jaguar's leadership and oncologists, will discuss the impact of diarrhea on cancer treatment and the importance of patient-physician dialogue. Jaguar's subsidiary, Napo Pharmaceuticals, has initiated a pivotal Phase 3 trial for crofelemer (Mytesi) in preventing cancer therapy-related diarrhea, currently approved for HIV/AIDS-related diarrhea relief.
Jaguar Health, Inc. (NASDAQ:JAGX) granted nonstatutory stock options for 45,000 shares to a new employee effective October 13, 2020. The options, at an exercise price of $0.315 per share, are part of the Company's Inducement Award Plan and aim to incentivize new hires. The options vest 25% after nine months and monthly thereafter over the next 27 months, contingent on continued employment. Jaguar Health specializes in plant-based gastrointestinal products, with its MYTESI product approved by the U.S. FDA for treating noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), unveiled the iAssist platform as part of its NapoCares patient support program. This web-based system automates the prescription process for Mytesi (crofelemer), an FDA-approved, plant-based treatment for diarrhea in HIV/AIDS patients. The platform enhances patient access by simplifying e-prescribing, prior authorizations, and eligibility checks, thereby promoting quicker treatment initiation. AssistRx developed iAssist, which also aids in tracking patient status and managing communications among healthcare providers, patients, and payers.
Jaguar Health has appointed Melissa Yeager, J.D. as Senior Vice President of Regulatory Affairs & Quality Assurance. With extensive experience in the pharmaceutical industry, Yeager's leadership is expected to enhance the regulatory and quality functions at Jaguar and its subsidiary, Napo Pharmaceuticals. This move supports the ongoing commercialization of Mytesi and the pivotal Phase 3 clinical trial for diarrhea prophylaxis in adult cancer patients. Mytesi, a plant-based, FDA-approved antidiarrheal, assists patients with HIV/AIDS on antiretroviral therapy.